Regulatory T cells in gastrointestinal tumors

References

• Wing K, Lindgren S, Kollberg G et al. CD4 T cell activation by myelin oligodendrocyte glycoprotein is suppressed by adult but not cord blood CD25+ T cells. Eur. J. Immunol.33(3), 579–587 (2003).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol.155(3), 1151–1164 (1995).
   PubMed Web of Science ®Google Scholar
• Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology18(5), 723–737 (1970).
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol.167(3), 1245–1253 (2001).
   PubMed Web of Science ®Google Scholar
• Wing K, Ekmark A, Karlsson H, Rudin A, Suri-Payer E. Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology106(2), 190–199 (2002).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol.4(4), 330–336 (2003).
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science299(5609), 1057–1061 (2003).
   PubMed Web of Science ®Google Scholar
• Brunkow ME, Jeffery EW, Hjerrild KA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet.27(1), 68–73 (2001).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.Nat. Genet.27(1), 20–21 (2001).
   PubMed Web of Science ®Google Scholar
• McHugh RS, Whitters MJ, Piccirillo CA et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity16(2), 311–323 (2002).
   PubMed Web of Science ®Google Scholar
• Kanamaru F, Youngnak P, Hashiguchi M et al. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J. Immunol.172(12), 7306–7314 (2004).
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science322(5899), 271–275 (2008).
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol.3(2), 135–142 (2002).
   PubMed Web of Science ®Google Scholar
• Stephens GL, McHugh RS, Whitters MJ et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol.173(8), 5008–5020 (2004).
   PubMed Web of Science ®Google Scholar
• Tone M, Tone Y, Adams E et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl Acad. Sci. USA100(25), 15059–15064 (2003).
   PubMed Web of Science ®Google Scholar
• Cote AL, Zhang P, O’Sullivan JA et al. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J. Immunol.186(1), 275–283 (2011).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Hirota K, Nagahama K et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity27(1), 145–159 (2007).
   PubMed Web of Science ®Google Scholar
• Becher D, Deutscher ME, Simpfendorfer KR et al. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. Eur. J. Immunol.40(10), 2778–2790 (2010).
   PubMedGoogle Scholar
• Wohlfert E, Belkaid Y. Role of endogenous and induced regulatory T cells during infections. J. Clin. Immunol.28(6), 707–715 (2008).
   PubMedGoogle Scholar
• Miyara M, Wing K, Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin. Immunol.123(4), 749–755; quiz 756–747 (2009).
   PubMedGoogle Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev.182, 18–32 (2001).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmental regulation of Foxp3 expression during ontogeny. J. Exp. Med.202(7), 901–906 (2005).
   PubMed Web of Science ®Google Scholar
• Wirnsberger G, Hinterberger M, Klein L. Regulatory T-cell differentiation versus clonal deletion of autoreactive thymocytes. Immunol. Cell Biol.89(1), 45–53 (2011).
   PubMed Web of Science ®Google Scholar
• Thornton AM, Korty PE, Tran DQ et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol.184(7), 3433–3441 (2010).
   PubMed Web of Science ®Google Scholar
• Groux H, O’Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature389(6652), 737–742 (1997).
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev.212, 28–50 (2006).
   PubMed Web of Science ®Google Scholar
• Maynard CL, Harrington LE, Janowski KM et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat. Immunol.8(9), 931–941 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell75(2), 263–274 (1993).
   PubMed Web of Science ®Google Scholar
• Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med.179(2), 589–600 (1994).
   PubMed Web of Science ®Google Scholar
• Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med.190(7), 995–1004 (1999).
   PubMed Web of Science ®Google Scholar
• Chen Y, Inobe J, Weiner HL. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell Immunol.178(1), 62–68 (1997).
   PubMedGoogle Scholar
• Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J. Cell Biol.119(5), 1017–1021 (1992).
   PubMed Web of Science ®Google Scholar
• Sun JB, Raghavan S, Sjoling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells. J. Immunol.177(11), 7634–7644 (2006).
   PubMed Web of Science ®Google Scholar
• Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin. Immunol.123(1), 18–29 (2007).
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med.198(12), 1875–1886 (2003).
   PubMed Web of Science ®Google Scholar
• Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-{β}. J. Immunol.174(3), 1446–1455 (2005).
   PubMed Web of Science ®Google Scholar
• Shevach EM, Tran DQ, Davidson TS, Andersson J. The critical contribution of TGF-β to the induction of Foxp3 expression and regulatory T cell function. Eur. J. Immunol.38(4), 915–917 (2008).
   PubMed Web of Science ®Google Scholar
• Jaensson E, Uronen-Hansson H, Pabst O et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J. Exp. Med.205(9), 2139–2149 (2008).
   PubMed Web of Science ®Google Scholar
• Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J. Clin. Invest.117(1), 60–69 (2007).
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med.340(11), 825–831 (1999).
   PubMed Web of Science ®Google Scholar
• Ekbom A. Risk of cancer in ulcerative colitis. J. Gastrointest. Surg.2(4), 312–313 (1998).
   PubMedGoogle Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol.27, 451–483 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res.66(2), 605–612 (2006).
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Chen L, Borges LP et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest.113(7), 1040–1050 (2004).
   PubMed Web of Science ®Google Scholar
• Schoppmann SF, Birner P, Stockl J et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol.161(3), 947–956 (2002).
   PubMed Web of Science ®Google Scholar
• Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin. Cancer Biol.18(5), 349–355 (2008).
   PubMed Web of Science ®Google Scholar
• Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev.222, 162–179 (2008).
   PubMed Web of Science ®Google Scholar
• Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology135(1), 234–243 (2008).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res.12(18), 5423–5434 (2006).
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Hiraoka N, Yamagami W et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res.13(3), 902–911 (2007).
   PubMed Web of Science ®Google Scholar
• Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology132(7), 2328–2339 (2007).
   PubMed Web of Science ®Google Scholar
• Petersen RP, Campa MJ, Sperlazza J et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer107(12), 2866–2872 (2006).
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Apetoh L et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells. Clin. Cancer Res.14(8), 2413–2420 (2008).
   PubMed Web of Science ®Google Scholar
• Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer98(5), 1089–1099 (2003).
   PubMed Web of Science ®Google Scholar
• Enarsson K, Lundgren A, Kindlund B et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin. Immunol.121(3), 358–368 (2006).
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhou S, Wang Y et al. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol.136(10), 1585–1595 (2010).
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Kono K, Kawaguchi Y et al. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br. J. Cancer98(1), 148–153 (2008).
   PubMed Web of Science ®Google Scholar
• Yuan XL, Chen L, Li MX et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin. Immunol.134(3), 277–288 (2010).
   PubMed Web of Science ®Google Scholar
• Kono K, Kawaida H, Takahashi A et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother.55(9), 1064–1071 (2006).
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res.69(20), 7895–7898 (2009).
   PubMed Web of Science ®Google Scholar
• Xue L, Lu HQ, He J et al. Expression of FOXP3 in esophageal squamous cell carcinoma relating to the clinical data. Dis. Esophagus23(4), 340–346 (2010).
   PubMedGoogle Scholar
• Maruyama T, Kono K, Izawa S et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis. Esophagus23(5), 422–429 (2010).
   PubMed Web of Science ®Google Scholar
• Zingg U, Montani M, Frey DM et al. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur. J. Surg. Oncol.36(7), 670–677 (2010).
   PubMed Web of Science ®Google Scholar
• Zingg U, Montani M, Frey DM, Dirnhofer S, Went P, Oertli D. Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer. Eur. J. Surg. Oncol.35(12), 1268–1272 (2009).
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Miyamoto M, Cho Y et al. Infiltrating regulatory T cell numbers is not a factor to predict patient’s survival in oesophageal squamous cell carcinoma. Br. J. Cancer98(7), 1258–1263 (2008).
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol.27(2), 186–192 (2009).
   PubMed Web of Science ®Google Scholar
• Le Gouvello S, Bastuji-Garin S, Aloulou N et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut57(6), 772–779 (2008).
   PubMed Web of Science ®Google Scholar
• Clarke SL, Betts GJ, Plant A et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE1, E129 (2006).
   PubMed Web of Science ®Google Scholar
• Ling KL, Pratap SE, Bates GJ et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun.7, 7 (2007).
   PubMedGoogle Scholar
• Michel S, Benner A, Tariverdian M et al. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br. J. Cancer99(11), 1867–1873 (2008).
   PubMed Web of Science ®Google Scholar
• Deng L, Zhang H, Luan Y et al. Accumulation of Foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin. Cancer Res.16(16), 4105–4112 (2010).
   PubMed Web of Science ®Google Scholar
• Frey DM, Droeser RA, Viehl CT et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer126(11), 2635–2643 (2010).
   PubMed Web of Science ®Google Scholar
• Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol.182(3), 318–324 (1997).
   PubMed Web of Science ®Google Scholar
• Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res.58(16), 3491–3494 (1998).
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313(5795), 1960–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Del Vecchio MT et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother.33(4), 435–441 (2010).
   PubMed Web of Science ®Google Scholar
• Erdman SE, Sohn JJ, Rao VP et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in APCMin/+ mice. Cancer Res.65(10), 3998–4004 (2005).
   PubMed Web of Science ®Google Scholar
• Gounaris E, Blatner NR, Dennis K et al. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res.69(13), 5490–5497 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke AR. Wnt signalling in the mouse intestine. Oncogene25(57), 7512–7521 (2006).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology137(4), 1270–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Chikazawa N, Tasaka T et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol. Immunother.59(5), 653–661 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang B, Jia H, Liu J et al. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. J. Immunol.185(12), 7199–7206 (2010).
   PubMed Web of Science ®Google Scholar
• Bonertz A, Weitz J, Pietsch DH et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest.119(11), 3311–3321 (2009).
   PubMed Web of Science ®Google Scholar
• Enarsson K, Johnsson E, Lindholm C et al. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin. Immunol.118(1), 24–34 (2006).
   PubMedGoogle Scholar
• Siewert C, Lauer U, Cording S et al. Experience-driven development: effector/memory-like αE+Foxp3+ regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells. J. Immunol.180(1), 146–155 (2008).
   PubMedGoogle Scholar
• Anz D, Mueller W, Golic M et al. CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int. J. Cancer DOI: 10.1002/ijc.25902 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol.178(4), 2155–2162 (2007).
   PubMed Web of Science ®Google Scholar
• Massague J. TGFβ in cancer. Cell.134(2), 215–230 (2008).
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7.J. Immunol.172(9), 5149–5153 (2004).
   PubMed Web of Science ®Google Scholar
• Liu VC, Wong LY, Jang T et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-β. J. Immunol.178(5), 2883–2892 (2007).
   PubMed Web of Science ®Google Scholar
• Hindley JP, Ferreira C, Jones E et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res.71(3), 736–746 (2011).
   PubMed Web of Science ®Google Scholar
• Kuczma M, Kopij M, Pawlikowska I, Wang CY, Rempala GA, Kraj P. Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells. PLoS ONE5(10), e13623 (2010).
   Google Scholar
• Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-β regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc. Natl Acad. Sci. USA101(13), 4572–4577 (2004).
   PubMed Web of Science ®Google Scholar
• Huber S, Schramm C, Lehr HA et al. Cutting edge: TGF-β signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J. Immunol.173(11), 6526–6531 (2004).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med.202(7), 919–929 (2005).
   PubMed Web of Science ®Google Scholar
• Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol.29(11), 514–522 (2008).
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int. J. Cancer121(11), 2473–2483 (2007).
   PubMed Web of Science ®Google Scholar
• Cao M, Cabrera R, Xu Y et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab. Invest.87(6), 582–590 (2007).
   PubMed Web of Science ®Google Scholar
• North RJ, Awwad M. Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology71(1), 90–95 (1990).
   PubMedGoogle Scholar
• Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J. Immunol.180(9), 5871–5881 (2008).
   PubMedGoogle Scholar
• Mougiakakos D, Johansson CC, Jitschin R, Bottcher M, Kiessling R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood117(3), 857–861 (2011).
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood113(15), 3542–3545 (2009).
   PubMed Web of Science ®Google Scholar
• Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science272(5258), 60–66 (1996).
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr. Opin. Immunol.12(3), 336–341 (2000).
   PubMed Web of Science ®Google Scholar
• Siewert C, Menning A, Dudda J et al. Induction of organ-selective CD4+ regulatory T cell homing. Eur. J. Immunol.37(4), 978–989 (2007).
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood108(2), 426–431 (2006).
   PubMed Web of Science ®Google Scholar
• Fu S, Yopp AC, Mao X et al. CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am. J. Transplant.4(1), 65–78 (2004).
   PubMed Web of Science ®Google Scholar
• Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J. Immunol.177(7), 4488–4494 (2006).
   PubMed Web of Science ®Google Scholar
• Iellem A, Mariani M, Lang R et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med.194(6), 847–853 (2001).
   PubMed Web of Science ®Google Scholar
• Ganss R, Arnold B, Hammerling GJ. Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur. J. Immunol.34(10), 2635–2641 (2004).
   PubMed Web of Science ®Google Scholar
• Ryschich E, Schmidt J, Hammerling GJ, Klar E, Ganss R. Transformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer97(6), 719–725 (2002).
   PubMed Web of Science ®Google Scholar
• Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res.68(14), 5972–5978 (2008).
   PubMed Web of Science ®Google Scholar
• Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol.12(8), 1145–1155 (2000).
   PubMed Web of Science ®Google Scholar
• Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity30(5), 636–645 (2009).
   PubMed Web of Science ®Google Scholar
• Ji Q, Gondek D, Hurwitz AA. Provision of granulocyte–macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J. Immunol.175(3), 1456–1463 (2005).
   PubMed Web of Science ®Google Scholar
• Boissonnas A, Scholer-Dahirel A, Simon-Blancal V et al. Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity32(2), 266–278 (2010).
   PubMed Web of Science ®Google Scholar
• Cao X, Cai SF, Fehniger TA et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity27(4), 635–646 (2007).
   PubMed Web of Science ®Google Scholar
• Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med.204(6), 1257–1265 (2007).
   PubMed Web of Science ®Google Scholar
• Borsellino G, Kleinewietfeld M, Di Mitri D et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood110(4), 1225–1232 (2007).
   PubMed Web of Science ®Google Scholar
• Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene29(39), 5346–5358 (2010).
   PubMed Web of Science ®Google Scholar
• Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (review). Int. J. Oncol.32(3), 527–535 (2008).
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res.15(20), 6348–6357 (2009).
   PubMed Web of Science ®Google Scholar
• Kullberg MC, Ward JM, Gorelick PL et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and γ interferon-dependent mechanism. Infect. Immun.66(11), 5157–5166 (1998).
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med.197(1), 111–119 (2003).
   PubMed Web of Science ®Google Scholar
• Kundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol.180(1), 55–61 (1997).
   PubMedGoogle Scholar
• Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol.22, 929–979 (2004).
   PubMed Web of Science ®Google Scholar
• Shime H, Yabu M, Akazawa T et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J. Immunol.180(11), 7175–7183 (2008).
   PubMed Web of Science ®Google Scholar
• Blatner NR, Bonertz A, Beckhove P et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc. Natl Acad. Sci. USA107(14), 6430–6435 (2010).
   PubMed Web of Science ®Google Scholar
• Chen ML, Pittet MJ, Gorelik L et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo.Proc. Natl Acad. Sci. USA102(2), 419–424 (2005).
   PubMed Web of Science ®Google Scholar
• Fahlen L, Read S, Gorelik L et al. T cells that cannot respond to TGF-β escape control by CD4(+)CD25(+) regulatory T cells. J. Exp. Med.201(5), 737–746 (2005).
   PubMed Web of Science ®Google Scholar
• Collison LW, Chaturvedi V, Henderson AL et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol.11(12), 1093–1101 (2010).
   PubMed Web of Science ®Google Scholar
• Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol. Rev.226, 248–262 (2008).
   PubMed Web of Science ®Google Scholar
• Enarsson K, Lundin BS, Johnsson E, Brezicka T, Quiding-Jarbrink M. CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur. J. Immunol.37(1), 282–291 (2007).
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res.70(20), 7800–7809 (2010).
   PubMed Web of Science ®Google Scholar
• Li X, Kostareli E, Suffner J, Garbi N, Hammerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol.40(12), 3325–3335 (2010).
   PubMed Web of Science ®Google Scholar
• Awwad M, North RJ. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J. Exp. Med.168(6), 2193–2206 (1988).
   PubMed Web of Science ®Google Scholar
• Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res.70(12), 4850–4858 (2010).
   PubMed Web of Science ®Google Scholar
• Malvicini M, Rizzo M, Alaniz L et al. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin. Cancer Res.15(23), 7256–7265 (2009).
   PubMedGoogle Scholar
• Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol.186(2), 807–815 (2011).
   PubMedGoogle Scholar
• Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine DOI: 10.1016/j.vaccine.2010.12.063 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Audia S, Nicolas A, Cathelin D et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin. Exp. Immunol.150(3), 523–530 (2007).
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhao J, Yang Z et al. CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin. Immunol.136(1), 21–29 (2010).
   PubMedGoogle Scholar
• Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res.59(13), 3128–3133 (1999).
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol.163(10), 5211–5218 (1999).
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother.25(3), 207–217 (2002).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115(12), 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.Int. J. Cancer120(12), 2723–2733 (2007).
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood112(3), 610–618 (2008).
   PubMed Web of Science ®Google Scholar
• Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother.28(6), 582–592 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Punt CJ, Lesterhuis WJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res.16(20), 5067–5078 (2010).
   PubMed Web of Science ®Google Scholar
• Okita R, Yamaguchi Y, Ohara M et al. Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int. J. Oncol.34(2), 563–572 (2009).
   PubMedGoogle Scholar
• Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol.18(2), 206–213 (2006).
   PubMed Web of Science ®Google Scholar
• Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother.58(5), 823–830 (2009).
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science271(5256), 1734–1736 (1996).
   PubMed Web of Science ®Google Scholar
• Lute KD, May KF Jr, Lu P et al. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood106(9), 3127–3133 (2005).
   PubMed Web of Science ®Google Scholar
• Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol.28(21), 3485–3490 (2010).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res.3(12 Pt 2), 2703–2707 (1997).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med.353(16), 1734–1736 (2005).
   PubMed Web of Science ®Google Scholar
• Karlsson M, Marits P, Dahl K et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann. Surg. Oncol.17(7), 1747–1757 (2010).
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol. Rev.239(1), 27–44 (2011).
   PubMed Web of Science ®Google Scholar